Vaccinex, Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
5
Ending by 2030
Feb 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 28, 2027The maintenance fee for ANTI-SEMA4D Antibodies and Epitopes (US 9,090,709) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 1 fee due Feb 20, 2027The maintenance fee for Use of SEMAPHORIN-4D Binding Molecules for Treating Neurodegenerative Disorders (US 10,385,136) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Use of Semaphorin-4D Binding Molecules to Promote Neurogenesis Following Stroke (US 10,494,440) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 3 fees due Jul 2 to 26, 2027 · next Jul 2
- 2 fees due Aug 2 to 4, 2027 · next Aug 2
- 1 fee due Sep 3, 2027The maintenance fee for Integral Membrane Protein Display on Poxvirus Extracellular Enveloped Virions (US 10,577,427) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
- 3 fees due Nov 5 to 14, 2027 · next Nov 5
Recent changes
- 1 term has ended since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,919,594 | Human ANTI-CD100 Antibodies In force · High confidence | In force | High confidence | |
| US 8,816,058 | Polynucleotides Encoding Anti-CD100 Antibodies or Antigen-binding Fragments Thereof In force · High confidence | In force | High confidence | |
| US 12,006,364 | ANTI-CD100 Antibodies and Methods for Using the Same In force · High confidence | In force | High confidence | |
| US 8,496,938 | ANTI-CD100 Neutralizing Antibodies and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 9,676,840 | Anti-CD100 Neutralizing Antibodies and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 11,274,149 | ANTI-CD100 Antibodies and Methods for Using the Same In force · High confidence | In force | High confidence | |
| US 9,605,055 | Anti-CD100 Antibodies and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 8,834,883 | Anti-VEGF Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,829,550 | Polynucleotides Encoding ANTI-CXCL13 Antibodies In force · High confidence | In force | High confidence | |
| US 11,534,488 | Use of SEMAPHORIN-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability In force · High confidence | In force | High confidence |
Also on record, not counted in the 41: 4 patents in force now held by others · 16 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 6 abandoned · 9 no status recorded